Unlock instant, AI-driven research and patent intelligence for your innovation.

Triazolopyridines

A compound, selected technology, applied in 24826A1 discloses a substituted, preparation of pharmaceutical compositions for treating or preventing diseases, and the field of intermediate compounds for preparing the compounds, which can solve problems such as low hydrolysis stability

Inactive Publication Date: 2015-11-25
BAYER IP GMBH
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0018] However, all of these compounds either exhibited ICs above 30 nM in the Mps-1 kinase assay using 2 mM ATP concentration 50 (potency less than 30nM), or exhibit low hydrolytic stability at pH 2, decay greater than 15% after 24h

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Triazolopyridines
  • Triazolopyridines
  • Triazolopyridines

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 011

[1146] N , N -Diethyl-4-{[6-(4-{[(4-fluorophenyl)acetyl]amino}phenyl)[1,2,4]triazolo[1,5- a ]pyridin-2-yl]amino}-3-methoxybenzamide

[1147]

[1148] Towards Int3.4 (150 mg) in a stirred suspension of toluene (3.5 mL) and NMP (0.5 mL), was added 4-bromo- N , N -Diethyl-3-methoxybenzamide (237mg), Pd 2 dba 3 (19mg) and rac-BINAP (26mg). The flask was degassed twice and backfilled with argon. The mixture was stirred at room temperature for 5 minutes. Cesium carbonate (405 mg) was added, the flask was degassed twice and backfilled with argon, and the mixture was heated to reflux for 20 h. Water was added, and the reaction mixture was extracted with ethyl acetate. The organic phase was washed with saturated sodium chloride solution, dried (sodium sulfate) and the solvent was removed in vacuo. Chromatography on silica gel gave a solid which was triturated with cyclohexane to give 27 mg of the title compound.

[1149]

[1150] from intermediate Int3.4 start with...

Embodiment 012

[1152] N -(4-{2-[(4-cyano-2-methoxyphenyl)amino][1,2,4]triazolo[1,5- a ]pyridin-6-yl}phenyl)-2-(4-fluorophenyl)acetamide

[1153]

[1154]

[1155] Starting Materials: Intermediates Int3.4 ; 4-Bromo-3-methoxybenzonitrile.

Embodiment 013

[1157] N -(4-{2-[(2-ethoxy-4-fluorophenyl)amino][1,2,4]triazolo[1,5- a ]pyridin-6-yl}phenyl)-2-(4-fluorophenyl)acetamide

[1158]

[1159]

[1160] Starting Materials: Intermediates Int3.4 ; 1-Bromo-2-ethoxy-4-fluorobenzene.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to triazolopyridine compounds of general formula (I): wherein R1, R2, R3, R4 and R5 are as given in the description and in the claims, to a process for the preparation of said compounds, to methods comprising the Pharmaceutical compositions and combinations of the compounds, the use of the compounds for the preparation of pharmaceutical compositions for the treatment or prevention of diseases, and intermediate compounds useful in the preparation of the compounds.

Description

[0001] The present invention relates to triazolopyridine compounds of general formula (I) as defined and described herein, to processes for the preparation of said compounds, to pharmaceutical compositions and combinations comprising said compounds, to said compounds for the preparation of The use of the pharmaceutical composition for treating or preventing diseases, and relates to an intermediate compound which can be used for preparing the compound. Background technique [0002] The present invention relates to compounds which inhibit the Mps-1 (monopolar spindle 1) kinase (also known as tyrosine threonine kinase, TTK). Mps-1 is a dual-specificity Ser / Thr kinase that plays a key role in the activation of the mitotic checkpoint (also known as the spindle checkpoint, spindle assembly checkpoint), thereby ensuring proper chromosome segregation during mitosis[ Abrieu A et al., Cell, 2001, 106, 83-93]. Each dividing cell must ensure that the replicated chromosomes are divided eq...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07D471/04A61K31/437A61P35/00
CPCC07D471/04A61P35/00A61P35/02A61P35/04A61P43/00A61K31/437A61K45/06
Inventor V.舒尔策D.科泽蒙德A.M.温格纳G.西迈斯特D.施特基希特P.利瑙H.席罗克H.布里姆
Owner BAYER IP GMBH